The global next generation sequencing market is entering a decisive expansion phase as clinical laboratories, pharmaceutical developers, and research institutions embed genomic data into core decision-making. Valued at USD 11.74 billion in 2025, the market is projected to reach USD 13.14 billion in 2026 and USD 34.47 billion by 2034, growing at a CAGR of 12.8% during the forecast period 2026–2034. The competitive landscape includes Illumina Inc., Thermo Fisher Scientific Inc., Roche Ltd., Qiagen, Oxford Nanopore Technologies, BGI, Bio-Rad Laboratories, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, Invitae Corporation, PierianDx, DNASTAR, Inc., and Genomatix GmbH.

Precision Medicine Anchors Demand in the NGS Market

Next generation sequencing has evolved from a research-centric technology into a core pillar of clinical diagnostics, drug discovery, and population genomics. Healthcare systems moving toward data-driven precision medicine models have accelerated adoption, and growing demand for personalized treatment is expected to increase the need for precise genetic profiling and targeted therapies.

The disease burden reinforces this shift. According to WHO, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022, while 53.5 million people were living within five years of a diagnosis. In oncology, NGS enables accurate tumor profiling and targeted therapies, while pharmaceutical and biopharmaceutical companies use it to identify genetic mutations, understand disease mechanisms, and develop treatments suited to individual patient profiles. Drug developers also rely on NGS for biomarker discovery, companion diagnostics, and precision medicine pipelines.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/next-generation-sequencing-ngs-market

Liquid Biopsy Strengthens Diagnostic Leadership

The diagnostics/infectious diseases segment dominated the next generation sequencing market in 2025 with an estimated 48.10% share. Advancement of liquid biopsy in cancer diagnosis and the global impact of COVID-19 drove this position. A liquid biopsy uses circulating tumor DNA as a cancer biomarker for real-time diagnosis, delivering exceptional sensitivity and low error rates when detecting low-level ctDNA in the bloodstream.

Whole Genome Sequencing Versus Targeted Sequencing

Whole genome sequencing covers the entire genome, including coding and non-coding regions, and suits rare disease research and comprehensive genomic studies. It carries the highest cost, very high data volume, and longer turnaround time, and requires complex data analysis. Targeted sequencing concentrates on specific genes or genomic regions, offering high depth for selected targets at lower cost, with low data volume and faster turnaround. Its clinical uses include cancer panels, inherited disease testing, and pathogen detection, though it is limited to predefined targets. Organizations therefore balance breadth of genomic insight against cost, speed, and data management capacity when deploying whole genome sequencing or targeted sequencing workflows.

AI-Powered Genomics Improves Workflow Efficiency

AI-powered genomics is becoming common across NGS workflows. Artificial intelligence and machine learning accelerate variant calling, improve mutation detection, and strengthen the interpretation of complex genomic datasets. These tools reduce manual intervention, raise sequencing accuracy, and lower operational costs. Applications range from automated sample preparation to real-time quality control, which is valuable in large-scale population genomics projects and clinical diagnostics where turnaround time and data accuracy are critical. High sequencing technology costs and data management challenges remain the principal restraints, so AI-powered genomics adoption is closely tied to scalability.

Regional Outlook for the Next Generation Sequencing Market

North America led the market in 2025 with an estimated 44.66% share, supported by strong healthcare infrastructure, the rising prevalence of chronic conditions, government genomics funding, and the presence of key players. The U.S. dominated the regional market. Asia Pacific is expected to grow at the highest rate, a CAGR of 16.76%, driven by rising R&D spending, chronic disease prevalence, and government incentives.

Strategic Implications for B2B Stakeholders

Clinical diagnostics, pharmaceutical R&D, CROs, and population genomics programs consistently require NGS solutions, giving providers strong revenue visibility. Product innovation continues: in April 2026, ACT Genomics upgraded its ACTDrug series NGS genomic profiling service to cover 101 clinically relevant genes with a seven-working-day turnaround. As sequencing costs decline and turnaround times shorten, the next generation sequencing market is positioned to become more accessible across diagnostics, research, and drug discovery.

More Trending Latest Reports By Polaris Market Research:

matcha-market

battery-energy-storage-system-market

top-10-virtual-desktop-infrastructure-vdi-companies-software-2025

activated-carbon-market

candle-market

predictive-maintenance-market

us-private-5g-network-market

creator-economy-platforms-market

ai-in-genomics-market`